Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-11-22

AUTHORS

Charles A. Kunos, Edward Chu, Jan H. Beumer, Mario Sznol, S. Percy Ivy

ABSTRACT

PurposeAdvanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition.MethodsA dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48–96 mg/m2) and i.v. cisplatin (20–75 mg/m2) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine–cisplatin combination. Secondary endpoints included the rate of triapine–cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323).ResultsThe MTD was 96 mg/m2 triapine daily days 1–4 and 75 mg/m2 cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%.ConclusionsThe triapine–cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway. More... »

PAGES

201-207

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x

DOI

http://dx.doi.org/10.1007/s00280-016-3200-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031872608

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27878356


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ribonucleotide Reductases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiosemicarbazones", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, 20892-9760, Rockville, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA", 
            "Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, 20892-9760, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kunos", 
        "givenName": "Charles A.", 
        "id": "sg:person.01315043163.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315043163.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chu", 
        "givenName": "Edward", 
        "id": "sg:person.01003652000.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003652000.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
            "Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA", 
            "University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beumer", 
        "givenName": "Jan H.", 
        "id": "sg:person.01154766121.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154766121.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ivy", 
        "givenName": "S. Percy", 
        "id": "sg:person.01234474774.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234474774.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nsmb.2007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041944342", 
          "https://doi.org/10.1038/nsmb.2007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1479-5876-10-79", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046418577", 
          "https://doi.org/10.1186/1479-5876-10-79"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-11-22", 
    "datePublishedReg": "2016-11-22", 
    "description": "PurposeAdvanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition.MethodsA dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48\u201396\u00a0mg/m2) and i.v. cisplatin (20\u201375\u00a0mg/m2) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine\u2013cisplatin combination. Secondary endpoints included the rate of triapine\u2013cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323).ResultsThe MTD was 96\u00a0mg/m2 triapine daily days 1\u20134 and 75\u00a0mg/m2 cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%.ConclusionsThe triapine\u2013cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-016-3200-x", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.3536166", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438856", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "79"
      }
    ], 
    "keywords": [
      "phase I trial", 
      "solid tumor malignancies", 
      "I trial", 
      "objective response", 
      "tumor malignancy", 
      "daily days 1", 
      "frequent grade 3", 
      "advanced-stage malignancies", 
      "dose-finding phase I trial", 
      "ResultsThe MTD", 
      "stable disease", 
      "primary endpoint", 
      "secondary endpoints", 
      "vulvar cancer", 
      "electrolyte abnormalities", 
      "adverse events", 
      "uterine cervix", 
      "cisplatin chemotherapy", 
      "grade 3", 
      "day 1", 
      "day 2", 
      "day 3", 
      "patients", 
      "malignancy", 
      "different schedules", 
      "reductase inhibition", 
      "trials", 
      "chemotherapy", 
      "pharmacokinetics", 
      "MTD", 
      "exploitable target", 
      "cisplatin", 
      "dose", 
      "endpoint", 
      "ribonucleotide reductase inhibition", 
      "bioavailability", 
      "Triapine", 
      "dyspnea", 
      "leukopenia", 
      "thrombocytopenia", 
      "cervix", 
      "therapy", 
      "cancer", 
      "abnormalities", 
      "disease", 
      "response", 
      "women", 
      "RNR inhibitors", 
      "inhibitors", 
      "inhibition", 
      "repair", 
      "combination", 
      "fatigue", 
      "target", 
      "levels", 
      "schedule", 
      "replication", 
      "rate", 
      "events", 
      "DNA replication", 
      "results", 
      "basis", 
      "supply", 
      "maximum", 
      "demand"
    ], 
    "name": "Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies", 
    "pagination": "201-207", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031872608"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-016-3200-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27878356"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-016-3200-x", 
      "https://app.dimensions.ai/details/publication/pub.1031872608"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_709.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-016-3200-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      21 PREDICATES      107 URIs      97 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-016-3200-x schema:about N256ccb596f444723a7b8ac87b094cd0c
2 N26a5a53cd6e4493fa420d0480aee859b
3 N28145373baf44f5a8be525eb9e34db92
4 N3a322c3ec61d4643a434f7397471b268
5 N502d43ba4f6e4bd792e93c939914280b
6 N58d1b77e0fcb453ebd6f2c4a73855fa3
7 N6bbd012ad4cf41c28db9dd75d0932ecd
8 N9243e45f911a490392efc623fd328181
9 N957e4b7997a240c683d3332fc9aa07e0
10 Na0562b9efada4b2b9eeffd3f493aa65b
11 Nb03cc65989d6436b8d888d403c3488c4
12 Nbcf60bc23485472eb6ec1989d36fcc14
13 Nbdc75292a8664af9900b018281631f09
14 Nde60405eee654223acaa627ab19832f8
15 Nfd24927b6ff548ec9711611e1ed65a64
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N7a5b58ede64c4d82b4ed88bda39b326b
19 schema:citation sg:pub.10.1038/nsmb.2007
20 sg:pub.10.1186/1479-5876-10-79
21 schema:datePublished 2016-11-22
22 schema:datePublishedReg 2016-11-22
23 schema:description PurposeAdvanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition.MethodsA dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48–96 mg/m2) and i.v. cisplatin (20–75 mg/m2) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine–cisplatin combination. Secondary endpoints included the rate of triapine–cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323).ResultsThe MTD was 96 mg/m2 triapine daily days 1–4 and 75 mg/m2 cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%.ConclusionsThe triapine–cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N11933c99c125407f96af4457918521c2
27 N5353c3c1693441f4bfdb86af9eca97c2
28 sg:journal.1088364
29 schema:keywords DNA replication
30 I trial
31 MTD
32 RNR inhibitors
33 ResultsThe MTD
34 Triapine
35 abnormalities
36 advanced-stage malignancies
37 adverse events
38 basis
39 bioavailability
40 cancer
41 cervix
42 chemotherapy
43 cisplatin
44 cisplatin chemotherapy
45 combination
46 daily days 1
47 day 1
48 day 2
49 day 3
50 demand
51 different schedules
52 disease
53 dose
54 dose-finding phase I trial
55 dyspnea
56 electrolyte abnormalities
57 endpoint
58 events
59 exploitable target
60 fatigue
61 frequent grade 3
62 grade 3
63 inhibition
64 inhibitors
65 leukopenia
66 levels
67 malignancy
68 maximum
69 objective response
70 patients
71 pharmacokinetics
72 phase I trial
73 primary endpoint
74 rate
75 reductase inhibition
76 repair
77 replication
78 response
79 results
80 ribonucleotide reductase inhibition
81 schedule
82 secondary endpoints
83 solid tumor malignancies
84 stable disease
85 supply
86 target
87 therapy
88 thrombocytopenia
89 trials
90 tumor malignancy
91 uterine cervix
92 vulvar cancer
93 women
94 schema:name Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies
95 schema:pagination 201-207
96 schema:productId N45119557e9104032ac33fc5d67d25ba0
97 N76208d63d6304f6ea8f367133d2f30e7
98 N96c478c089654df181c39b33854a1589
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031872608
100 https://doi.org/10.1007/s00280-016-3200-x
101 schema:sdDatePublished 2022-09-02T16:00
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N6cd7f21dcd074508835d314b3a342eb4
104 schema:url https://doi.org/10.1007/s00280-016-3200-x
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N11933c99c125407f96af4457918521c2 schema:issueNumber 1
109 rdf:type schema:PublicationIssue
110 N256ccb596f444723a7b8ac87b094cd0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Thiosemicarbazones
112 rdf:type schema:DefinedTerm
113 N26a5a53cd6e4493fa420d0480aee859b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Male
115 rdf:type schema:DefinedTerm
116 N28145373baf44f5a8be525eb9e34db92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N3a322c3ec61d4643a434f7397471b268 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Middle Aged
121 rdf:type schema:DefinedTerm
122 N45119557e9104032ac33fc5d67d25ba0 schema:name dimensions_id
123 schema:value pub.1031872608
124 rdf:type schema:PropertyValue
125 N502d43ba4f6e4bd792e93c939914280b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Neoplasm Staging
127 rdf:type schema:DefinedTerm
128 N5353c3c1693441f4bfdb86af9eca97c2 schema:volumeNumber 79
129 rdf:type schema:PublicationVolume
130 N58d1b77e0fcb453ebd6f2c4a73855fa3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Infusions, Intravenous
132 rdf:type schema:DefinedTerm
133 N6bbd012ad4cf41c28db9dd75d0932ecd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Pyridines
135 rdf:type schema:DefinedTerm
136 N6cd7f21dcd074508835d314b3a342eb4 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 N76208d63d6304f6ea8f367133d2f30e7 schema:name doi
139 schema:value 10.1007/s00280-016-3200-x
140 rdf:type schema:PropertyValue
141 N7a5b58ede64c4d82b4ed88bda39b326b rdf:first sg:person.01315043163.01
142 rdf:rest N9fa1ea63d5834ae68419ffba2c18853f
143 N9243e45f911a490392efc623fd328181 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Female
145 rdf:type schema:DefinedTerm
146 N957e4b7997a240c683d3332fc9aa07e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Antineoplastic Combined Chemotherapy Protocols
148 rdf:type schema:DefinedTerm
149 N96c478c089654df181c39b33854a1589 schema:name pubmed_id
150 schema:value 27878356
151 rdf:type schema:PropertyValue
152 N9c1e6abe32994e4e9f1fc5f2e7fb32f9 rdf:first sg:person.01234474774.39
153 rdf:rest rdf:nil
154 N9fa1ea63d5834ae68419ffba2c18853f rdf:first sg:person.01003652000.28
155 rdf:rest Nfb16072e1912497a984b20c95e77b4b7
156 Na0562b9efada4b2b9eeffd3f493aa65b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Aged
158 rdf:type schema:DefinedTerm
159 Na61ee9b434744971922bf2d80b5de88f rdf:first sg:person.0706626451.72
160 rdf:rest N9c1e6abe32994e4e9f1fc5f2e7fb32f9
161 Nb03cc65989d6436b8d888d403c3488c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Ribonucleotide Reductases
163 rdf:type schema:DefinedTerm
164 Nbcf60bc23485472eb6ec1989d36fcc14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Neoplasms
166 rdf:type schema:DefinedTerm
167 Nbdc75292a8664af9900b018281631f09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Aged, 80 and over
169 rdf:type schema:DefinedTerm
170 Nde60405eee654223acaa627ab19832f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cisplatin
172 rdf:type schema:DefinedTerm
173 Nfb16072e1912497a984b20c95e77b4b7 rdf:first sg:person.01154766121.36
174 rdf:rest Na61ee9b434744971922bf2d80b5de88f
175 Nfd24927b6ff548ec9711611e1ed65a64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Adult
177 rdf:type schema:DefinedTerm
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
182 schema:name Oncology and Carcinogenesis
183 rdf:type schema:DefinedTerm
184 sg:grant.2438856 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-016-3200-x
185 rdf:type schema:MonetaryGrant
186 sg:grant.3536166 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-016-3200-x
187 rdf:type schema:MonetaryGrant
188 sg:journal.1088364 schema:issn 0344-5704
189 1432-0843
190 schema:name Cancer Chemotherapy and Pharmacology
191 schema:publisher Springer Nature
192 rdf:type schema:Periodical
193 sg:person.01003652000.28 schema:affiliation grid-institutes:grid.21925.3d
194 schema:familyName Chu
195 schema:givenName Edward
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003652000.28
197 rdf:type schema:Person
198 sg:person.01154766121.36 schema:affiliation grid-institutes:grid.21925.3d
199 schema:familyName Beumer
200 schema:givenName Jan H.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154766121.36
202 rdf:type schema:Person
203 sg:person.01234474774.39 schema:affiliation grid-institutes:grid.48336.3a
204 schema:familyName Ivy
205 schema:givenName S. Percy
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234474774.39
207 rdf:type schema:Person
208 sg:person.01315043163.01 schema:affiliation grid-institutes:grid.48336.3a
209 schema:familyName Kunos
210 schema:givenName Charles A.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315043163.01
212 rdf:type schema:Person
213 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.47100.32
214 schema:familyName Sznol
215 schema:givenName Mario
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
217 rdf:type schema:Person
218 sg:pub.10.1038/nsmb.2007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041944342
219 https://doi.org/10.1038/nsmb.2007
220 rdf:type schema:CreativeWork
221 sg:pub.10.1186/1479-5876-10-79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046418577
222 https://doi.org/10.1186/1479-5876-10-79
223 rdf:type schema:CreativeWork
224 grid-institutes:grid.21925.3d schema:alternateName University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
225 University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA
226 schema:name Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
227 University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
228 University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA
229 rdf:type schema:Organization
230 grid-institutes:grid.47100.32 schema:alternateName Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA
231 schema:name Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA
232 rdf:type schema:Organization
233 grid-institutes:grid.48336.3a schema:alternateName Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
234 Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, 20892-9760, Rockville, MD, USA
235 schema:name Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
236 Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, 20892-9760, Rockville, MD, USA
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...